

Batch recall of Mivacron Inj 0.2% and Nimbex Inj 2mg/mL

The Department of Health (DH) today (24 October) endorsed a licensed drug wholesaler, namely Aspen Pharmacare Asia Limited O/B Aspen Pharmacare Asia Limited (Aspen) to recall a total of six batches of the following two products from the market as a precautionary measure due to the potential quality issue.

Name of product	Hong Kong registration number	Batch number
Mivacron Inj 0.2%	HK-37866	XPC19
Nimbex Inj 2mg/mL	HK-42333	XP1SQ
		XPC1G
		XPC6W
		XP1V5
		XP1VF

The DH received notification from Aspen that investigation by the overseas manufacturer of the products revealed deficiencies in manual visual inspection. According to the investigation, potentially not all glass particles in the ampoules have been detected during inspection of the above batches. As a precautionary measure, Aspen voluntarily recalls the affected batches of the two products from the market.

Mivacron Inj 0.2%, containing mivacurium and Nimbex Inj 2mg/mL, containing cisatracurium, are prescription medicines used for adjunct to general anesthesia. According to Aspen, the above batches of products have been imported into Hong Kong. Mivacron Inj 0.2% has been supplied to both the Hospital Authority and private hospitals and Nimbex Inj 2mg/mL has been supplied to private hospitals.

Aspen has set up a hotline (3902 6652) to answer related enquiries.

So far, the DH has not received any adverse reaction reports in connection with the above batches of products. The DH will closely monitor the recall.

Patients who have used the above product should consult their healthcare professionals if in doubt.

Ends/Friday, Oct 24, 2025

Issued at HKT 21:00